CD19 and myeloid sarcoma: Clinically, these results confirm that anti‐CD20 therapy effectively reduces MS disease activity before conception through to the postpartum period, minimal transfer into breastmilk, and reassuring infant development, growth, and CD19 levels when exposed to anti‐CD20 therapies via breastfeeding.